Extracellular matrix stiffness controls cardiac valve myofibroblast activation through epigenetic remodeling
Open Access
- 22 August 2022
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 7 (3) , e10394
Abstract
Aortic valve stenosis (AVS) is a progressive fibrotic disease that is caused by thickening and stiffening of valve leaflets. At the cellular level, quiescent valve interstitial cells (qVICs) activate to myofibroblasts (aVICs) that persist within the valve tissue. Given the persistence of myofibroblasts in AVS, epigenetic mechanisms have been implicated. Here, we studied changes that occur in VICs during myofibroblast activation by using a hydrogel matrix to recapitulate different stiffnesses in the valve leaflet during fibrosis. We first compared the chromatin landscape of qVICs cultured on soft hydrogels and aVICs cultured on stiff hydrogels, representing the native and diseased phenotypes respectively. Using assay for transposase‐accessible chromatin sequencing (ATAC‐Seq), we found that open chromatin regions in aVICs were enriched for transcription factor binding motifs associated with mechanosensing pathways compared to qVICs. Next, we used RNA‐Seq to show that the open chromatin regions in aVICs correlated with pro‐fibrotic gene expression, as aVICs expressed higher levels of contractile fiber genes, including myofibroblast markers such as alpha smooth muscle actin (αSMA), compared to qVICs. In contrast, chromatin remodeling genes were downregulated in aVICs compared to qVICs, indicating qVICs may be protected from myofibroblast activation through epigenetic mechanisms. Small molecule inhibition of one of these remodelers, CREB Binding Protein (CREBBP), prevented qVICs from activating to aVICs. Notably, CREBBP is more abundant in valves from healthy patients compared to fibrotic valves. Our findings reveal the role of mechanical regulation in chromatin remodeling during VIC activation and quiescence and highlight one potential therapeutic target for treating AVS.Keywords
Funding Information
- American Heart Association (20POST3521111, 20PRE35200068)
- Burroughs Wellcome Fund
- Defense Advanced Research Projects Agency (W911NF‐19‐2‐0024)
- National Institutes of Health (FHL142223, K99 HL148542, R01 GM29090, R01HL132353, R01HL142935, RHL117138‐05, RO1 GM125871, T32 HL007822)
- National Institutes of Health (1S10OD012300)
This publication has 64 references indexed in Scilit:
- Identification of a novel flow-mediated gene expression signature in patients with bicuspid aortic valveJournal of Molecular Medicine, 2012
- Redirecting Valvular Myofibroblasts into Dormant Fibroblasts through Light-mediated Reduction in Substrate ModulusPLOS ONE, 2012
- A Novel Acetylation Cycle of Transcription Co-activator Yes-associated Protein That Is Downstream of Hippo Pathway Is Triggered in Response to SN2 Alkylating AgentsJournal of Biological Chemistry, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Sirt1 Inhibits Resistin Expression in Aortic StenosisPLOS ONE, 2012
- Calcific Aortic Valve Disease: Not Simply a Degenerative ProcessCirculation, 2011
- Fibroblasts and Myofibroblasts: What Are We Talking About?Journal of Cardiovascular Pharmacology, 2011
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- Photodegradable Hydrogels for Dynamic Tuning of Physical and Chemical PropertiesScience, 2009
- Klf4 reverts developmentally programmed restriction of ground state pluripotencyDevelopment, 2009